Linagliptin + Metformin


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Type 2 diabetes mellitus
Adult: Available preparations:
Conventional tab:
Linagliptin 2.5 mg and metformin 500 mg
Linagliptin 2.5 mg and metformin 850 mg
Linagliptin 2.5 mg and metformin 1,000 mg
Linagliptin 5 mg and metformin 1,000 mg
Extended-release tab:
Linagliptin 2.5 mg and metformin 1,000 mg
Linagliptin 5 mg and metformin 1,000 mg
1 tab bid (conventional) or once daily (extended-release) based on patient’s current regimen, effectiveness, and tolerability. Max: Linagliptin 5 mg and metformin 2,000 mg daily.
Renal Impairment
Severe (GFR <30 mL/min): Contraindicated.
Hepatic Impairment
Contraindicated.
Cách dùng
Should be taken with food.
Chống chỉ định
Diabetic pre-coma, acute or chronic metabolic acidosis (e.g. diabetic ketoacidosis, lactic acidosis), alcoholism or acute alcohol intoxication, acute or chronic disease that may cause hypoxia (e.g. cardiac or resp failure, recent MI, shock), conditions which may alter renal function (e.g. severe infection, dehydration). Intravascular admin of iodinated contrast agents.  Hepatic and severe renal impairment (GFR <30 mL/min).
Thận trọng
Patient w/ CHF, history of pancreatitis, and those who are exposed to stress (e.g. infection, fever, trauma, surgery). Not intended for the treatment of diabetic ketoacidosis or type 1 DM. Renal impairment (GFR 30-45 mL/min). Pregnancy and lactation.
Phản ứng phụ
Significant: Hypoglycaemia, severe arthralgia, bullous pemphigoid, vit B12 deficiency. Rarely, serious hypersensitivity reactions (e.g. anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity).
GI: Diarrhoea, decreased appetite, nausea, pancreatitis, vomiting, constipation.
Resp: Nasopharyngitis, cough.
Genitourinary: UTI.
Endocrine: Hyperlipidaemia, hypertriglyceridaemia, wt gain.
Musculoskeletal: Back pain, pain in extremity.
Dermatologic: Pruritus.
Potentially Fatal: Lactic acidosis, acute pancreatitis.
MonitoringParameters
Monitor glycosylated Hb (HbA1c), serum glucose, hepatic and renal function, haematologic parameters prior to initiation of therapy and periodically thereafter. Monitor signs or symptoms of pancreatitis.
Tương tác
Concomitant cationic drugs that interfere w/ renal tubular transport systems (e.g. ranolazine, vandetanib, dolutegravir, cimetidine) may increase metformin levels. Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, OCs, sympathomimetics, phenytoin, niacin, Ca channel blockers and isoniazid may produce hyperglycaemia which may lead to loss of glycaemic control. Increased risk of lactic acidosis w/ topiramate or other carbonic anhydrase inhibitors (e.g. zonisamide, acetazolamide, dichlorphenamide). Plasma concentration of linagliptin may be decreased by strong inducers of P-glycoprotein (e.g. rifampicin) and may be increased by strong P-glycoprotein inhibitors (e.g. ritonavir). Linagliptin may increase risk of hypoglycaemia when used in combination w/ sulfonylureas or insulin.
Food Interaction
Food decreases the extent and slightly delays absorption of metformin. Alcohol may potentiate the effect of metformin on lactate metabolism. Reduced serum level w/ St John’s wort.
Tác dụng
Description: Linagliptin inhibits dipeptidylpeptidase-4 (DPP-4), an enzyme that inactivates incretin hormones. Inhibition of DPP-4 results in an increase in the levels of incretin hormones [e.g. glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)] which regulate glucose homeostasis by increasing insulin synthesis and release from pancreatic β-cells and decreasing glucagon secretion from pancreatic α-cells, leading to reduced hepatic glucose production. Metformin is a biguanide antidiabetic agent that reduces hepatic glucose production by decreasing gluconeogenesis and glycogenolysis, decreases intestinal absorption of glucose and enhances insulin sensitivity by increasing peripheral utilisation and uptake of glucose.
Pharmacokinetics:
Absorption: Linagliptin: Rapidly absorbed from the GI tract. Absolute bioavailability: Approx 30%. Time to peak plasma concentration: W/in approx 1.5 hr. Metformin: Slowly and incompletely absorbed from the GI tract. Reduced if taken w/ food. Absolute bioavailability: Approx 50-60%. Time to peak plasma concentration: 2.5 hr.
Distribution: Linagliptin: Extensively distributed to body tissues. Plasma protein binding: Concentration dependent: 99% (low concentration); 70-80% (high concentration). Volume of distribution: Approx 1110 L. Metformin: Partitions into erythrocytes; concentrates in kidney, liver, and GI tract. Crosses the placenta and enters breast milk in small amounts. Volume of distribution: 654 ± 358 L.
Excretion: Linagliptin: Mainly via faeces (approx 80%, as unchanged drug); urine (5%, as unchanged drug). Elimination half-life: Approx 12 hr. Metformin: Via urine (90% as unchanged drug). Plasma elimination half-life: Approx 2 hr.
Đặc tính

Chemical Structure Image
Linagliptin

Source: National Center for Biotechnology Information. PubChem Database. Linagliptin, CID=10096344, https://pubchem.ncbi.nlm.nih.gov/compound/Linagliptin (accessed on Jan. 22, 2020)


Chemical Structure Image
Metformin

Source: National Center for Biotechnology Information. PubChem Database. Metformin, CID=4091, https://pubchem.ncbi.nlm.nih.gov/compound/Metformin (accessed on Jan. 20, 2020)

Bảo quản
Store at 25°C. Protect from moisture.
Phân loại MIMS
Phân loại ATC
A10BD11 - metformin and linagliptin ; Belongs to the class of combinations of oral blood glucose lowering drugs. Used in the treatment of diabetes.
References
Anon. Linagliptin and Metformin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 01/08/2017.

Anon. Linagliptin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 01/08/2017.

Anon. Metformin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 01/08/2017.

Buckingham R (ed). Linagliptin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/08/2017.

Buckingham R (ed). Metformin Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/08/2017.

Jentadueto Tablet, Film Coated (Boehringer Ingelheim Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 01/08/2017.

Jentadueto XR Tablet, Film Coated, Extended Release (Boehringer Ingelheim Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 01/08/2017.

McEvoy GK, Snow EK, Miller J et al (eds). Linagliptin. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 01/08/2017.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Linagliptin + Metformin từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in